FDA warned Elle Pharm that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
What happened
FDA reviewed the website www.ellepharm.com and observed that it offers unapproved and misbranded injectable botulinum toxin drug products for sale to U.S. consumers. FDA cited "Hutox 100ui" and "Hutox 100" as an example and noted website claims for "blepharospasm correction" and "hyperhidrosis." FDA said there are no approved applications for these Hutox products.
What FDA found
FDA says the website offers a new drug without an approved FDA application, so it is unapproved and cannot be legally sold in interstate commerce.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]FDA says the labeling lacks adequate directions for use by a layperson, making the drug misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]FDA says the product is a prescription drug that is not safe for use except under a licensed practitioner's supervision.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]
What FDA wants
FDA asks Elle Pharm to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to review its websites, product labels, and promotional materials. It asks for a written response within 15 working days describing corrective steps, how recurrence will be prevented, and related documentation.
Who should pay attention
- companies selling injectable aesthetic drugs online
- U.S. clinicians who buy or administer botulinum toxin
- consumers considering online botulinum toxin purchases
This is a summary. Read the original letter on fda.gov.